Enrollment velocity rarely moves a trial’s strategic calendar by half a year, but that is exactly what happened with Kymera’s BROADEN2 study: the Phase 2b atopic dermatitis trial in KT-621, its oral STAT6 degrader, closed enrollment roughly six months ahead of its original schedule, pulling the topline readout from mid-2027 to year-end 2026 and compressing the runway to Phase 3 initiation to mid-2027. For a company betting its clinical identity on targeted protein degradation rather than biologics, that acceleration is not a footnote.
The enrollment speed matters beyond optics. Atopic dermatitis is a crowded therapeutic space where biologics have held the efficacy standard for years, and an oral agent that can match biologic-level depth of target suppression faces a high burden of convenience proof. KT-621 has already shown up to 98% STAT6 degradation in peripheral blood in Phase 1 data, and the BROADEN2 design will test whether that biochemical signal translates into clinically meaningful skin clearance in moderate-to-severe patients. Rapid enrollment suggests investigators and patients are willing to find out. That kind of site-level enthusiasm is informative on its own: investigators who cannot fill slots in a field full of injectable options generally do not rush into an oral degrader trial unless the early safety and tolerability profile is genuinely reassuring.
Meanwhile, Kymera is not running a single-program operation. Its IRF5 degrader KT-579 is in a healthy volunteer Phase 1 with data expected in the fourth quarter of 2026, to be followed by a proof-of-concept trial in lupus. And Sanofi has formally dosed the first participant in a Phase 1 for KT-485, a second-generation IRAK4 degrader in hidradenitis suppurativa, triggering a $20 million milestone. Three clinical-stage programs moving simultaneously, all oral, all in immunology, backed by $1.5 billion in cash with runway into 2029. That capitalization gives Kymera the option to run Phase 3 in AD without a partnership forcing the design, which is a structural advantage most clinical-stage companies at this point do not have.
The single number worth tracking now is the year-end 2026 BROADEN2 EASI or IGA response rate against placebo. If KT-621 posts biologic-competitive efficacy in an oral daily pill, the STAT6 degrader category moves from scientifically interesting to commercially serious, and the Phase 3 design conversation shifts from “if” to “how fast.”
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
